With the focus ”Transforming the Future of Biologics” the PEGS Boston Virtual Summit brought a dynamic online learning and networking experience with research at the forefront of biotherapeutics development.
If you were keen to keep up to date with the ever-changing nature of Gene Therapy and discover the latest tactics, the emerging therapies stream was the place to be. With a surge in interest and R&D investment for uses genes to treat or prevent diseases, experimental Gene therapy technique move quickly from bench to clinic, and the emerging therapies stream presented an opportunity to meet industry forerunners and gain insights into strategies and program development.
Our own Dr. Michael Tovey, Managing Director of Svar Life Science France, held a keynote presentation in the vector design, delivery and characterization session on “Quantification of the Immune Response to AAV Mediated Gene Therapy” presenting data on how a highly sensitive iLite® reporter assay under the control of an AAV-responsive chimeric promoter can provide a highly sensitive, rapid and precise method for quantifying the immune response to a wide range of recombinant AAV vectors.
We took part in inspiring keynote presentations, interacted with participants global, joined live Q&A panels and breakout discussions and received a library of presentations to digest over time.
“AAV-Mediated Gene Therapy is a fascinating new development which offers promising therapies for a multitude of severe diseases with an unmet clinical need. In this context quantification of the immune response to AAV-Mediated Gene Therapy will play a paramount role in the future. Svar Life Science is proud to be at the forefront of this new therapeutic area. Together with global pharmaceutical companies we facilitate and accelerate the development and release of various new gene therapy approaches” says Dr. Michael Schwenkert, Chief Technology Officer at Svar Life Science.